Wilson J A, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn A L, Hart M K
Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702-5011, USA.
Science. 2000 Mar 3;287(5458):1664-6. doi: 10.1126/science.287.5458.1664.
To determine the ability of antibodies to provide protection from Ebola viruses, monoclonal antibodies (mAbs) to the Ebola glycoprotein were generated and evaluated for efficacy. We identified several protective mAbs directed toward five unique epitopes on Ebola glycoprotein. One of the epitopes is conserved among all Ebola viruses that are known to be pathogenic for humans. Some protective mAbs were also effective therapeutically when administered to mice 2 days after exposure to lethal Ebola virus. The identification of protective mAbs has important implications for developing vaccines and therapies for Ebola virus.
为了确定抗体提供针对埃博拉病毒的保护能力，制备了针对埃博拉糖蛋白的单克隆抗体（mAb）并评估其疗效。我们鉴定了几种针对埃博拉糖蛋白上五个独特表位的保护性单克隆抗体。其中一个表位在所有已知对人类致病的埃博拉病毒中是保守的。一些保护性单克隆抗体在小鼠暴露于致死性埃博拉病毒2天后给药时也具有有效的治疗作用。保护性单克隆抗体的鉴定对于开发埃博拉病毒疫苗和疗法具有重要意义。
